Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split

The company intends the consolidation to address Nasdaq’s minimum bid price requirement for continued listing.

Rhea-AI Summary

Cellyan Biotechnology (Nasdaq: HKPD) expects to implement a 1-for-20 reverse stock split at market opening on October 26, 2026.

The board-approved consolidation covers issued and unissued Class A and Class B ordinary shares. Every twenty outstanding ordinary shares will become one, with Class A shares continuing split-adjusted trading under HKPD. The company intends the split primarily to regain compliance with the Nasdaq Capital Market’s minimum bid price requirement. Shareholders’ percentage ownership will remain unchanged except for fractional-share adjustments, which will be rounded up to whole shares at the participant level.

0 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• None.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.1-for-20 reverse split is intended primarily to regain compliance with Nasdaq’s minimum bid price requirement.

Argus 15 min delay 6 alerts

-23.04% vs previous close $0.09 last price 22.2x rel. volume Open Argus

Details

Market move: HKPD -23.04% vs previous close. 1-for-20 reverse stock split

-19.4% Trough in 5 min

$0.08 – $0.11 Day Range

$4.26M Mkt Cap at Last Price

On Oct 21, the day this news came out, the latest delayed price for HKPD is 23.04% below the previous close. Argus tracked a trough of -19.4% from its starting point during tracking. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $0.09. Relative volume is exceptionally heavy at 22.2x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Reverse split ratio: 1-for-20 Effective date: October 26, 2026 Par value per share: $0.001 before; $0.02 after

Reverse split ratio

1-for-20

Applies to issued and unissued Class A and Class B ordinary shares

Effective date

October 26, 2026

Effective at market opening

Par value per share

$0.001 before; $0.02 after

Ordinary shares

Historical Context

1 past event · Latest: Jul 16

1 event

1. Jul 16

   Nasdaq compliance extension

   24h Move

   -11.7%

   Nasdaq granted 180 additional days to meet the $1.00 minimum bid-price requirement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

reverse stock split, par value, cusip

3 terms

reverse stock split financial

"expects to implement a 1-for-20 reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

par value financial

"par value $0.001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

cusip technical

"The new CUSIP number for the Company’s Ordinary Shares"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, announced that it expects to implement a 1-for-20 reverse stock split, or consolidation of its issued and unissued Class A ordinary shares and Class B ordinary shares, par value $0.001 per share (the “Ordinary Shares”), effective at the opening of market of October 26, 2026 (the “Reverse Stock Split”). Trading in the Class A Ordinary Shares on a split-adjusted basis will continue on Nasdaq on October 26, 2026 under the symbol “HKPD.” The new CUSIP number for the Company’s Ordinary Shares post-Reverse Stock Split is G6365B112.

Upon the effectiveness of the Reverse Stock Split, every twenty issued and outstanding Ordinary Shares will be consolidated into one Ordinary Shares. The Company’s Ordinary Shares have a par value of $0.001 per share prior to the Reverse Stock Split and will have a par value of $0.02 per share following the Reverse Stock Split. Fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share at a participant level. The Reverse Stock Split affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s outstanding Ordinary Shares, except for adjustments that may result from the treatment of fractional shares. The Reserves Stock Split was approved by the Company’s board of directors.

The Reverse Stock Split is primarily intended to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. However, there can be no assurance that the Company will regain compliance with such requirement within the applicable compliance period or maintain compliance with Nasdaq’s continued listing requirement thereafter.

About Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.

Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting OTC pharmaceutical products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers. 

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. All forward-looking statements, expressed or implied, in this release are based only on information currently available to us and speak only as of the date on which they are made. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this release. Except as otherwise required by applicable law, we disclaim any duty to publicly update any forward-looking statement to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in our filings with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries please contact:   

Cellyan Biotechnology Co., Ltd
Media Contact: andy@cell-yan.com 
Investor Relations: stella@cell-yan.com   

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Cellyan Biotechnology’s HKPD reverse stock split take effect, and what is the ratio?

Cellyan Biotechnology expects its 1-for-20 reverse stock split to take effect at market opening on October 26, 2026. Every twenty outstanding ordinary shares will be consolidated into one, and Class A shares will continue trading on a split-adjusted basis under HKPD.

How will Cellyan Biotechnology’s reverse split affect shareholders’ ownership and fractional shares?

The reverse split will leave shareholders’ percentage ownership unchanged, except for adjustments from fractional shares. Fractional shares will be rounded up to the nearest whole share at the participant level.